Trials / Withdrawn
WithdrawnNCT03390738
Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase II, open label, single arm, single agent study using nivolumab in patients who failed 2 or more lines of previous chemotherapy for recurrent/metastatic NPC (At least 1 line should include platinum based chemotherapy)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-05-01
- Completion
- 2019-06-01
- First posted
- 2018-01-04
- Last updated
- 2021-05-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03390738. Inclusion in this directory is not an endorsement.